Paclitaxel-loaded poly(D,L-lactide-co-glycolide) nanoparticles for radiotherapy in hypoxic human tumor cells in vitro

Cancer Biology and Therapy

Volumn 7, Issue 6, 2008, Pages 911-916

  Jin, Cheng ^a   Bai, Ling ^b   Wu, Hong ^a   Liu, Junye ^a   Guo, Zhen ^a   Chen, Jingyuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of Pathology   (China)

Author keywords

Cellular uptake; Drug delivery; Human tumor cells; Hypoxia; Nanoparticle; Paclitaxel; Radiotherapy

Indexed keywords

NANOPARTICLE; PACLITAXEL; POLYGLACTIN; ANTINEOPLASTIC AGENT; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID POLYGLYCOLIC ACID COPOLYMER; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; SOLVENT;

ARTICLE; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL STRUCTURE; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; ENCAPSULATION; FLOW CYTOMETRY; HELA CELL; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPOXIC CELL; IN VITRO STUDY; MICROPHOTOGRAPHY; QUANTITATIVE ANALYSIS; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIZATION; RADIOTHERAPY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE; ANOXIA; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; COCULTURE; KINETICS; METHODOLOGY;

ANOXIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; DRUG DELIVERY SYSTEMS; HELA CELLS; HUMANS; KINETICS; LACTIC ACID; NANOPARTICLES; PACLITAXEL; POLYGLYCOLIC ACID; RADIOTHERAPY; SOLVENTS;

EID: 46749133479     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.6.5912     Document Type: Article

References (40)

1. Attawia MA, Borden MD, Herbert KM, Katti DS, Asrari F, Uhrich KE, Laurencin CT. Regional drug delivery with radiation for the treatment of Ewing's sarcoma.In vitro development of a taxol release system. J Control Release 2001; 71:193-202.
2. Bush RS, Jenkin RDT, Allt WEC, Beale FA, Bean H, Dembo AJ, Pringle JG. Definitive evidence for hypoxic cells influence in the cure in cancer therapy. Br J Cancer 1978; 37:302-6.
3. Couvreur P, Kante B, Lenaerts V. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci 1980; 69:199-202.
4. Couvreur P, Puisicux F. Nano- and microparticles for the delivery of polypeptides and proteins. Adv Drug Del Rev 1993; 10:141-62.
5. Dorr RT. Pharmacology and toxicology of Cremophor EL diluent. Ann Pharmacother 1994; 28:11-4.
6. Feng SS, Huang GF. Effects of emulsifiers on the controlled release of paclitaxel (Taxol®) from nanospheres of biobiodegradable polymers. J Control Release 2001; 71:53-69.
7. Feng SS, Huang GF, Mu L. Nanospheres of biodegradable polymers: a system for clinical administration of an anticancer drug paclitaxel (Taxol®). Ann Acad Med Singapore 2000; 29:633-9.
8. Feng SS, Mu L, Win KY, Huang GF. Nanoparticles of biodegradable polymers for clinical administration of paclitaxel. Curr Med Chem 2004; 11:413-24.
9. Fiuorillo A, Tranfa F, Canale F, Fariello I, D'Amore R, De Chiara C, Vassallo P, Muto P, De Rosa G, Bonavolonta G. Primary Ewing's sarcoma of the maxilla, a rare and curable localization. Report of two cases, successfully treated by radiotherapy and systemic chemotherapy. Cancer Lett 1996; 103:177-82.
10. Fjallskog ML, Frii L, Bergh J. Is cremophor, solvent for paclitaxel, cytotoxic? Lancet 1993; 342:876.
11. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 2002; 83:273-86.
12. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in ridaotherapy. Br J Radiol 1953; 26:638-48.
13. Holland SJ, Tighe BJ. Biodegradable Polymers, in: D. Garderton, T. Jones (Eds.), Adv Pharmaceutical Science Vol. 6, Academic Press, New York 1992; 101-64.
14. Horsman MR. Nicotinamide and other benzamide analogs as agents for overcoming hypoxic cell radiation resistance in tumors. Acta Oncol 1995; 34:571-87.
15. Jin C, Wu H, Liu J, Bai L, Guo G. The effect of paclitaxel-loaded nanoparticles with radiation on hypoxic MCF-7 cells. J Clin Pharm Ther 2007; 32:41-7.
16. Konan YN, Gurny R, Allemann E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int J Pharm 2002; 233:239-52.
17. Labhasetwar V, Song C, Humphrey W, Shebuski R, Levy RJ. Arterial uptake of biodegradable nanoparticles: effect of surface modi.cations. J Pharm Sci 1998; 87:1229-34.
18. Leroux JC, Doelker E, Gurny R. The use of drug-loaded nanoparticles in cancer chemotherapy, in: S. Benita (Ed.), Microencapsulation: Methods and Industrial Applications. Marcel Dekker, New York 1996; 535-75.
19. Lopes NM, Adams EG, Pitts TW, Bhuyan BK. Cell kill kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32:235-42.
20. Magenheim B, Benita S. Nanoparticle characterization: a comprehensive physicochemical approach. STP Pharma Sci 1991; 1:221-41.
21. Mason KA, Milas L, Peters U. Effect of taxol (Paclitaxel) alone and in combination with radiation on the gastrointestinal mucosa. Int J Radiat Oncol Biol Phys 1995; 32:1381-9.
22. Meerum Terwogt JM, Nuijen B, Ten Bokkel Huinink WW. Alternative formulations of paclitaxel. Cancer Treat Rev 1997; 23:87-95.
23. Monsky WL, Fukumura D, Gohongi T. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999; 59:4129-35.
24. Mu L, Feng SS. Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly(lactic-co-glycolicacid) microspheres prepared by spray drying technique with lipid/ cholesterol emulsifiers. J Control Release 2001; 76:239-54.
25. Mu L, Feng SS. Vitamin E TPGS used as emulsifier in the solvent extraction/ evaporation technique for fabrication of polymeric nanospheres for controlled release of paclitaxel. J Control Release 2002; 80:129-44.
26. Mu L, Feng SS. PLGA/TPGS nanoparticles for controlled release of paclitaxel: Effects of the emulsifier and the drug loading ratio. Pharm Res 2003; 20:1864-72.
27. Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, Matsumura Y. NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer 2006; 95:601-6.
28. Rolland A. Clinical pharmacokinetics of doxorubicin in hepatoma patients after a single intravenous injection of free or nanoparticle-bound anthracycline. Int J Pharm 1989; 54:113-21.
29. Rowinsky EK, Donehover RC. Paclitaxel (taxol). N Engl J Med 1995; 332:1004-14.
30. Rowinsky EK, Onetto N, Canetta RM, Arbuck SG. Taxol: the first of the taxane, an important new class of antitumour agents. Semin Oncol 1992; 19:646-62.
31. Sinclair WK, Morton RA. X-ray sensitization during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 1966; 29:450-75.
32. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm 2002; 235:179-92.
33. Tatou E, Mossiat C, Maupoil V. Effects of cyclosporin and cremophor on working rat heart and incidence of myocardial lipid peroxidation. Pharmacology 1996; 52:1-7.
34. Terasima R, Tolrnach LJ. X-ray sensitivity and DNA synthesis in synchronous populations of HeLa cells. Science 1963; 140:490-2.
35. Tishler RB, Geard CR, Hall EJ, Schiff PB. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992a; 52:495-7.
36. Tishler RB, Schiff PB, Geard CR, Hall EJ. Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992b; 22:613-7.
37. Wang J, Ng CW, Win KY, Shoemarkers P, Lee TK, Feng SS, Wang CH. Release of paclitaxel from polylactide-co-glycolide (PLGA) microparticles and discs under irradiation. J Microencapsul 2003; 20:317-27.
38. Wani MC, Taylor HL, Wall ME. Plant tumor agents VI. The isolation and structure of Taxol, a novel antieukemic and antitumor agent from taxus brevifolia. J Am Chem Soc 1971; 93:2325-7.
39. Win KY, Feng SS. Effects of particle size and surface coating on cellular uptake of polymeric nanoparticles for oral delivery of anticancer drugs. Biomaterials 2005; 26:2713-22.
40. Withers HR, Mason K, Reid BO, Dubravsky N, Barkely HT, Brown BM. Response of mouse intestine to neurons and gamma rays in relation to dose and division cycle. Cancer 1974; 34:39-47.